- Subscribe Today
- Training & Events
- Buyer's Guide
Abbott and Kos Pharmaceuticals Inc. on November 6 announced a definitive agreement for Abbott to acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion, net of cash currently held by
"Kos Pharmaceuticals is an excellent strategic fit for Abbott, both scientifically and commercially," said Miles D. White, Abbott’s chairman and chief executive officer. "This acquisition expands Abbott's presence in the lipid management market and will provide several on-market and late-stage pipeline products.
"Since being founded in 1988 by our current chairman emeritus Michael Jaharis and chairman Daniel Bell, Kos has pioneered the HDL therapy area in the
Under the terms of the agreement, Abbott will make a tender offer for all of the outstanding stock of Kos Pharmaceuticals for $78 per share or $3.7 billion, net of cash currently held by
The transaction is structured as a tender offer for all outstanding shares of Kos Pharmaceuticals followed by a merger. The transaction is subject to customary closing conditions, including antitrust clearance under the Hart- Scott Rodino Act and acquisition of a majority of the outstanding Kos Pharmaceuticals shares in the tender offer. Shareholders owning a majority of the shares of Kos Pharmaceuticals' common stock have entered into agreements under which they agreed to tender their shares or have their shares acquired by Abbott.